Phentolamine Ophthalmic Solution Vehicle

DRUG2 trials

Sponsors

Ocuphire Pharma, Inc.

Conditions

DilationMydriasis

Phase 3

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

CompletedNCT05134974

Ocuphire Pharma, Inc.Dilation, Mydriasis

Start: 2021-11-18End: 2022-03-29Updated: 2023-08-29

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

CompletedNCT05223478

Ocuphire Pharma, Inc.Dilation, Mydriasis

Start: 2021-12-17End: 2022-04-28Updated: 2023-09-05